Skip to content

Embr Thermal Device for Hot Flash Management in Prostate Cancer

Feasibility of the Embr Thermal Device for Management of Hot Flashes in Men With Prostate Cancer

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04892914
Enrollment
57
Registered
2021-05-19
Start date
2021-05-28
Completion date
2021-12-05
Last updated
2022-04-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hot Flashes, Prostate Cancer

Keywords

androgen deprivation therapy, orchiectomy, prostate carcinoma, night sweats, hormone therapy

Brief summary

This study is being conducted to evaluate if the Embr thermal device is useful for men who experience bothersome hot flashes as a result of prostate cancer treatment.

Detailed description

The Embr thermal device is a smart device that is worn on the inside of the wrist. It is about the size of a smart watch. The Embr thermal device produces cooling or warming temperature sensations that make some people feel slightly cooler or warmer. This objective of this study is to evaluate if the Embr thermal device is useful for men who experience bothersome hot flashes as a result of prostate cancer treatment. The study will take place over 4 weeks. The primary outcome is feasibility of the Embr thermal device in men with prostate cancer. Secondary outcomes include preliminary efficacy of the device, which will include the change in hot flash interference sleep measures (sleep impairment and fatigue). This is a remote study--all study assessments will be completed electronically.

Interventions

DEVICEEmbr thermal device

Participants use the Embr thermal device for 4 weeks

Sponsors

Embr Labs, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Embr thermal device

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Have received a diagnosis of prostate cancer and have received treatment with GnRH agonist or antagonist therapy or orchiectomy at least 1 month prior to enrollment. * May have received prior definitive radiation therapy or surgery (\>60 days prior to study). * Have bothersome hot flashes (occurrence ≥ 28 times per week and at least moderately bothersome). * Presence of hot flashes for \>30 days prior to study entry. * Have a working smartphone (iPhone 6 or greater; or Android 8.0 or greater). * Willing to downloading and use the Embr thermal device companion app on their phone * Willing to wear the Embr thermal device for 4 weeks, and charge and sync the device daily * In order to complete the mandatory patient-completed measures, participants must be able to speak and/or read English

Exclusion criteria

* Planned treatment with chemotherapy and/or any medical intervention that will impact hot flashes, sleep, or other daily activities of daily life during the 4-week study. * History of a known sleep disorder, other than insomnia (eg, obstructive sleep apnea, restless leg syndrome), or medical or psychiatric condition that affects sleep, or undergoing treatment for insomnia. * History of cognitive impairment or dysfunction. * Seizure history, history of recurrent falls, or known brain metastases. * Uncontrolled intercurrent illness. * Individuals with a second malignancy other than non-melanoma skin cancers. * Individuals taking psychotropic medications or illicit drugs that may alter cognition, concentration, or behavior. * Individuals taking prescription sleep medications. * Individuals who report consuming more than 7 alcoholic beverages/week and/or frequent alcohol consumption within 2 hours prior to bed.

Design outcomes

Primary

MeasureTime frameDescription
Embr thermal device usage, average number of minutes per day per participantWeeks 0 to 4Number of minutes logged with the Embr device.
Embr thermal device usage, average number of sessions per day per participantWeeks 0 to 4Number of sessions logged with the Embr device.

Secondary

MeasureTime frameDescription
PROMIS Sleep Disturbance short form 4a, change in scoreWeek 0, 2, 4The PROMIS Sleep Disturbance SF 4a is a 4-item self report measure of perceived difficulties falling asleep and staying asleep, as well as sleep satisfaction. The 4 items are scored 1-5 where 1 is good quality and 5 is poor quality for a total score range of 4 (good quality) to 20 (poor quality).
Hot Flash Related Daily Interference Scale (HFRDIS), change in scoreWeek 0, 2, 4The Hot Flash Related Daily Interference Scale is a 10-item self-report measure that assesses the interference on several aspects of functioning associated with hot flashes. This valid and reliable self-report measure is widely used in prostate cancer research. Scores range from 0 to 100, with higher scores indicating greater interference.
PROMIS Sleep-Related Impairment short form 8a, change in scoreWeeks 0, 2, 4The PROMIS Sleep-Related Impairment SF 8a is an 8-item self reported measure of perceived alertness, sleepiness, and tiredness during usual waking hours. The 8 items are scored 1-5 where 1 is good quality and 5 is poor quality for a total score range of 8 (good quality) to 40 (poor quality).
Epworth sleepiness scale, change in scoreWeek 0, 2, 4The Epworth Sleepiness Scale is a widely used measure of daytime sleepiness. Scores range from 0 to 24; scores of greater than 10 indicate excessive daytime sleepiness.

Other

MeasureTime frameDescription
Temperature-related quality of life and symptoms, change in scoreWeek 0, 2, 4Self-report measure of temperature-related quality of life and symptoms. Scores range from 0 to 100 with higher scores indicating greater quality of life.
Vasomotor Symptom SurveyWeek 0, 1, 2, 3, 4Self-report 10-question survey of hot flash and night sweat number, duration, interference, bothersome rating, and control of interference. Score range 0 to 86 with higher score indicating greater negative impact of vasomotor symptoms.
User acceptanceWeek 4Self-report 8-question survey at end of study.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026